Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$170.26+2.68 (+1.60%)
Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%
Gilead Sciences pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Gilead Sciences's pe ratio was 17.7× on Jul 31, 2026, against 23.8× a year earlier. Over the last 5 years it ranged from 11.7× to 300.8×, with a median of 19.4×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 17.7× | −1.4 |
| 2025 | Dec 31, 2025 | 19.1× | −89.2 |
| 2024 | Oct 31, 2024 | 108.3× | +90.9 |
| 2023 | Dec 29, 2023 | 17.4× | −15.0 |
| 2022 | Dec 30, 2022 | 32.4× | +20.0 |
| 2021 | Dec 31, 2021 | 12.4× | −47.7 |
| 2020 | Dec 31, 2020 | 60.1× | +29.0 |
| 2019 | Dec 31, 2019 | 31.1× | −21.0 |
| 2018 | Dec 31, 2018 | 52.1× | +44.0 |
| 2017 | Dec 29, 2017 | 8.2× | +1.5 |
| 2016 | Dec 30, 2016 | 6.6× | −2.6 |
| 2015 | Dec 31, 2015 | 9.3× | −7.4 |
| 2014 | Dec 31, 2014 | 16.6× | −24.4 |
| 2013 | Dec 31, 2013 | 41.0× | +18.1 |
| 2012 | Dec 31, 2012 | 23.0× | +11.1 |
| 2011 | Dec 30, 2011 | 11.9× | +0.3 |
| 2010 | Dec 31, 2010 | 11.6× | −5.3 |
| 2009 | Dec 31, 2009 | 16.9× | – |
See a number that looks wrong?